Corrigendum to "Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer" [Biochem. Biophys. Res. Commun. 680 (2023) 161-170]
Biochem Biophys Res Commun. 2023 Dec 17:686:149085.
doi: 10.1016/j.bbrc.2023.10.017.
Epub 2023 Oct 13.
1 Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
2 Department of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.
3 Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
4 National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan; Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
5 Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. Electronic address: clarehf@tmu.edu.tw.
6 Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address: ycl@tmu.edu.tw.